Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ortataxel vs fotemustine in recurrent glioblastoma
2012-003618-15Phase 2Completed
- Sponsor
- Mario Negri Institute for Pharmacological Research
- Start
- Jul 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in glioblastoma (GBM) comparing Ortataxel monotherapy with Fotemustine calibration arm (2 arms). Primary endpoint: 6-month progression-free survival (PFS-6). Started Jul 2013; status: completed.
02
Drugs
ortataxelfotemustine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2012-003618-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003618-15.